ReviewJournal of clinical and experimental hepatology2014
The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.
Review in Journal of clinical and experimental hepatology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 74 citations in OpenAlex.
- A transcriptomic five-gene signature for sorafenib response prediction in hepatocellular carcinoma: clinical promise and limitations.Journal of gastrointestinal oncology · 2026Article
- NAT10 drives hepatocellular carcinoma progression through SQLE-mediated cholesterol biosynthesis and is targetable by remodelin.iScience · 2026Article
- Spontaneous Rupture of Hepatocellular Carcinoma With Fatal Outcome in a Patient Taking Direct-Acting Antivirals.Cureus · 2023Article
- Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma.Scientific reports · 2023Article
- Metastatic Hepatocellular Carcinoma Masquerading as an Expansile Osteolytic Lesion in Scapula: A Rare Case of Isolated Appendicular Skeletal Metastatic Involvement of Hepatocellular Carcinoma at Initial Presentation.World journal of nuclear medicine · 2023Article
- Clinical Management of Liver Cancer in India and Other Developing Nations: A Focus on Radiation Based Strategies.Oncology and therapy · 2021Review
- Transarterial Radioembolization (TARE) withSouth Asian journal of cancer · 2021Article
- Genetic and biochemical studies of hepatic carcinoma in the Egyptian population.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2021Article
- Indian Council of Medical Research consensus document on hepatocellular carcinoma.The Indian journal of medical research · 2020Article
- RISC assembly and post-transcriptional gene regulation in Hepatocellular Carcinoma.Genes & diseases · 2020Review
- A survey of clinical practices among oncologists regarding hepatitis B screening in patients with cancer.The Indian journal of medical research · 2020Article
- Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints.World journal of gastroenterology · 2020Review
- Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand?Ultrasonography (Seoul, Korea) · 2019Article
- Staging systems of hepatocellular carcinoma: A review.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2018Review
- Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis.World journal of gastroenterology · 2018Review
- Current topics in the surgical treatments for hepatocellular carcinoma.Annals of gastroenterological surgery · 2018Review
- INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements.Journal of clinical and experimental hepatology · 2018Review
- The Warsaw Proposal for the Use of Extended Selection Criteria in Liver Transplantation for Hepatocellular Cancer.Annals of surgical oncology · 2017Article
- Clinical application of protein induced by vitamin K antagonist-II as a biomarker in hepatocellular carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.World journal of gastroenterology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 13 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the major causes of morbidity, mortality and healthcare expenditure in patients with chronic liver disease. There are no consensus guidelines on diagnosis and management of HCC in India. The Indian National Association for Study of the Liver (INASL) set up a Task-Force on HCC in 2011, with a mandate to develop consensus guidelines for diagnosis and management of HCC, relevant to disease patterns and clinical practices in India. The Task-Force first identified various contentious issues on various aspects of HCC and these issues were allotted to individual members of the Task-Force who reviewed them in detail. The Task-Force used the Oxford Center for Evidence Based Medicine-Levels of Evidence of 2009 for developing an evidence-based approach. A 2-day round table discussion was held on 9th and 10th February, 2013 at Puri, Odisha, to discuss, debate, and finalize the consensus statements. The members of the Task-Force reviewed and discussed the existing literature at this meeting and formulated the INASL consensus statements for each of the issues. We present here the INASL consensus guidelines (The Puri Recommendations) on prevention, diagnosis and management of HCC in India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.